New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Journal of Hematology and Oncology Année : 2023

New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting

Résumé

Immunotherapy has revolutionized cancer treatment, but currently, immuno-oncology agents have not been approved for patients with soft tissue sarcomas. However, there is growing evidence suggesting that immunotherapy could be an effective therapeutic strategy for this group of diseases. Here, we reviewed the latest advances of immunotherapy trials from the 2023 American Society of Clinical Oncology Annual Meeting, including some novel and encouraging combination regimens. Further research is still needed to fully understand the optimal use of these agents in sarcoma treatment.

Domaines

Cancer
Fichier principal
Vignette du fichier
3. Journal of Hemato & Onco 2023.pdf (767.04 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte

Dates et versions

hal-04431492 , version 1 (01-02-2024)

Identifiants

Citer

Matthieu Roulleaux-Dugage, Antoine Italiano. New immunotherapy strategies for patients with sarcomas: highlights from the 2023 ASCO annual meeting. Journal of Hematology and Oncology, 2023, 16, ⟨10.1186/s13045-023-01486-6⟩. ⟨hal-04431492⟩
2 Consultations
4 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More